Vanda Pharmaceuticals reported $4.96M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 544.86M 180.93M Sep/2026
J&J USD 49.04B 5.95B Jun/2026
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Ligand Pharmaceuticals USD 1.13B 679.48M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.29B 11M Jun/2026
Novartis USD 48.31B 1.31B Sep/2026
Pfizer USD 62.67B 523M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Takeda JPY 4.58T 364.32B Sep/2026
Teva Pharmaceutical Industries USD 16.98B 110M Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Veracyte USD 40.11M 774K Jun/2026